Trust Point’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.69M Buy
10,288
+155
+2% +$39.7K 0.2% 59
2026
Q2
$2.55M Buy
10,133
+1,780
+21% +$383K 0.22% 57
2026
Q1
$1.82M Buy
8,353
+1,363
+19% +$302K 0.16% 74
2025
Q4
$1.6M Buy
6,990
+59
+0.9% +$13.4K 0.13% 78
2025
Q3
$1.6M Sell
6,931
-582
-8% -$119K 0.13% 78
2025
Q2
$1.39M Sell
7,513
-268
-3% -$49.8K 0.13% 83
2025
Q1
$1.63M Sell
7,781
-2,713
-26% -$527K 0.15% 74
2024
Q4
$1.86M Sell
10,494
-1,241
-11% -$228K 0.13% 78
2024
Q3
$2.32M Buy
11,735
+1,760
+18% +$328K 0.17% 62
2024
Q2
$1.71M Sell
9,975
-483
-5% -$80K 0.14% 73
2024
Q1
$1.9M Buy
10,458
+904
+9% +$156K 0.15% 72
2023
Q4
$1.48M Buy
+9,554
New +$1.39M 0.12% 91

Other funds holding ABBV

Trust Point's ABBV Position: Q3 2026 in Review

Trust Point increased its AbbVie (ABBV) stake by 1.5% in Q3 2026, buying an estimated $39.7K and bringing the position to 10,288 shares worth $2.69M. The position accounts for 0.2% of the portfolio, ranked #59.

Trust Point first reported a position in ABBV in Q4 2023 and has held it in 12 quarters since. 3,830 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Trust Point held 10,288 shares of AbbVie worth $2.69M as of Q3 2026.
  • Trust Point bought 155 AbbVie shares in Q3 2026, an estimated $39.7K.
  • AbbVie made up 0.2% of Trust Point's portfolio in Q3 2026, its #59 holding.
  • Trust Point first reported a position in AbbVie in Q4 2023 and has held it in 12 quarters since.
  • 3,830 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Trust Point's 13F filing for Q3 2026, filed 27 Oct 2026.